TREVENA, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-12-09: Form 8-K; Period of report 2019-12-04; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2019-11-04: Form 8-K; Period of report 2019-11-04; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2019-09-06: Form 8-K; Period of report 2019-09-03; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2019-08-07: Form 8-K; Period of report 2019-08-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-12-09 | 8-K | 2019-12-04 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | tm1924641-1_8k.htm |
| 2019-11-04 | 8-K | 2019-11-04 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On November 4, 2019, Trevena, Inc. (the “Company”) issued a press release announcing: (i) its financial results for the quarter ended September 30, 2019, (ii) top line data results of the healthy volunteer QT study of oliceridine, and (iii) initiation of the TRV250 acute migraine proof-of-concept study. 7.01 In connection with its press release dated November 4, 2019, the Company will hold a conference call and webcast on November 4, 2019 at 8:30 a.m. | a19-21769_18k.htm |
| 2019-09-06 | 8-K | 2019-09-03 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On September 3, 2019, Trevena, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued inclusion on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Notice”). | a19-18309_18k.htm |
| 2019-08-07 | 8-K | 2019-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | a19-16748_18k.htm |
| 2019-06-27 | 8-K | 2019-06-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On June 25, 2019, John P. Hamill ceased to serve as the principal financial and accounting officer of Trevena, Inc. (the “Company”), effective immediately. 7.01 On June 27, 2019, the Company issued a press release announcing the appointment of Mr. Shin as Chief Financial Officer. | a19-12181_18k.htm |
| 2019-05-17 | 8-K | 2019-05-16 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 In connection with the Annual Meeting, there were 92,353,638 shares outstanding as of the March 19, 2019 record date, of which 67,952,024 shares, or approximately 73.57%, were present or represented by proxy at the Annual Meeting. | a19-10129_18k.htm |
| 2019-05-10 | 8-K | 2019-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | a19-9780_18k.htm |
| 2019-04-17 | 8-K | 2019-04-17 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a19-8321_28k.htm |
| 2019-03-13 | 8-K | 2019-03-13 | 2.02 Results of Operations and Financial Condition | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. | a19-6098_28k.htm |
| 2019-03-07 | 8-K | 2019-03-05 | 8.01 Other Events | 8.01 In February 2016, based on the preliminary evidence from Trevena’s (the “Company”) Phase 2 clinical studies of oliceridine, the U.S. Food and Drug Administration (“FDA”) granted Breakthrough Therapy designation to oliceridine for the management of moderate to severe acute pain. | a19-6098_18k.htm |
| 2019-03-01 | 8-K | 2019-02-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 27, 2019, the Board (i) approved a cash incentive award for fiscal year 2018 under the Trevena, Inc. Incentive Compensation Plan (the “ICP”) to be made to Carrie L. Bourdow, the President and Chief Executive Officer (the “CEO”) of the Company, and (ii) ratified ICP cash incentive awards for fiscal year 2018 that were approved by the Compensation Committee of the Board for the Company’s senior vice presidents. | a19-5626_18k.htm |
| 2019-02-11 | 8-K | 2019-02-11 | 8.01 Other Events | 8.01 On February 11, 2019, Trevena, Inc. (the “Company”) received notice from Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market confirming that for the last 10 consecutive business days, the closing bid price of the Company’s common stock has been equal to or in excess of the $1.00 per share minimum bid price requirement for continued listing, as set forth in Nasdaq Listing Rule 5450(a)(1). | a19-4450_18k.htm |
| 2019-02-01 | 8-K | 2019-01-29 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 The information under Item 1.01 of this Current Report on Form 8-K regarding the Wainwright Warrants is incorporated herein by reference. | a19-3859_28k.htm |
| 2019-01-30 | 8-K | 2019-01-29 | 8.01 Other Events | 8.01 On January 30, 2019, Trevena, Inc. (the “Company”) issued a press release announcing that it entered into securities purchase agreements dated January 29, 2019 (the “Purchase Agreements”) with two healthcare–focused institutional investors (the “Purchasers”). | a19-3646_18k.htm |
| 2019-01-28 | 8-K | 2019-01-28 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 The information under this caption and contained in the press release attached hereto as Exhibit 99.1 is furnished by Trevena, Inc. (the “Company”) in accordance with Securities Exchange Commission Release No. 33-8216. 8.01 On January 28, 2019, the Company issued a press release announcing the receipt of the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the oliceridine New Drug Application (NDA). | a19-3483_18k.htm |